Daniel Loeb's SPRY Position Overview
Daniel Loeb (via Third Point LLC) currently holds 1 M shares of ARS Pharmaceuticals, Inc. (SPRY) worth $8.03 M, representing 0.39% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Daniel Loeb has initiated a new position in SPRY, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 443,763 shares.
Analysis based on 13F filings available since 2013 Q2
Daniel Loeb's ARS Pharmaceuticals (SPRY) Holding Value Over Time
Track share changes against reported price movement
Quarterly ARS Pharmaceuticals (SPRY) Trades by Daniel Loeb
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +443,763 | Add 79.78% | 1 M | $8.03 |
| Q4 2025 | +556,237 | New Buy | 556,237 | $11.65 |
Daniel Loeb's ARS Pharmaceuticals Investment FAQs
Daniel Loeb first purchased ARS Pharmaceuticals, Inc. (SPRY) in Q4 2025, acquiring 556,237 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Daniel Loeb has held ARS Pharmaceuticals, Inc. (SPRY) for 2 quarters since Q4 2025.
Daniel Loeb's largest addition to ARS Pharmaceuticals, Inc. (SPRY) was in Q4 2025, adding 556,237 shares worth $6.48 M.
According to the latest 13F filing for Q1 2026, Daniel Loeb's firm, Third Point LLC, owns 1,000,000 shares of ARS Pharmaceuticals, Inc. (SPRY), valued at approximately $8.03 M.
As of the Q1 2026 filing, ARS Pharmaceuticals, Inc. (SPRY) represents approximately 0.39% of Daniel Loeb's publicly disclosed stock portfolio, making it one of their key holdings.
Daniel Loeb's peak holding in ARS Pharmaceuticals, Inc. (SPRY) was 1,000,000 shares, as reported at the end of Q1 2026.